Noxopharm funds its next lupus trial with placement and note conversion

• $1.5 million placement at $0.042 a share, plus a non-underwritten $1 million SPP
• $3.78 million of shareholder convertible notes to convert into approximately 90 million shares
• SOF-SKN extension study targeting around 15 cutaneous lupus patients from Q1 2027
• September-quarter cash fell to A$31,000 after A$663,000 of operating outflows